Last reviewed · How we verify
Gabitril
At a glance
| Generic name | Gabitril |
|---|---|
| Sponsor | Cephalon |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Population Pharmacokinetics of Antiepileptic in Pediatrics
- Treating Schizophrenia by Correcting Abnormal Brain Development (PHASE3)
- Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder (PHASE3)
- A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice (PHASE4)
- Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma (PHASE1, PHASE2)
- Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study. (PHASE4)
- Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence (PHASE1)
- Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gabitril CI brief — competitive landscape report
- Gabitril updates RSS · CI watch RSS
- Cephalon portfolio CI